Kim K, Huang H, He L, Parida P, Marquez-Palencia M, Carrillo D, Miyata J, Stevens C, Kapur P, Brugarolas J, Brekken RA, Malladi S. Cell competition shapes metastatic latency and relapse. Cancer Discov. 2022 Sep 13:CD-22-0236.
Huang H*, Wang Z, Zhang Y, Brekken RA*. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022 Jun 13;40(6):656-673.e7. (*Corresponding Authors)
Zhang Y, Huang H, Coleman M, Ziemys A, Gopal P, Kazmi S, Brekken RA. VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight. 2021 Oct 21;e150735.
Zhang Y, Arner EN, Rizvi A, Toombs JE, Huang H, Warner SL, Foulks JM, Brekken RA. Axl inhibitor TP-0903 reduces metastasis and therapy resistance in pancreatic cancer. Mol Cancer Ther. 2021 Oct 21;molcanther.0293.2021.
Huang H, Brekken RA. Location matters: Profiling diffuse type gastric cancer at the single cell level. Clin Cancer Res. 2021 Sep 23;clincanres.2935.2021.
Deng J, Kang Y, Cheng C, Li X, Dai B, Katz MH, Men T, Kim MP, Koay E, Huang H, Brekken RA, Fleming JB. DDR1-induced Neutrophil Extracellular Traps Drive Pancreatic Cancer Metastasis. JCI Insight. 2021 Jul 8;146133.
Du W, Phinney NZ, Huang H, Wang Z, Westcott J, Toombs JE, Zhang Y, Beg MS, Wilkie TM, Lorens JB, Brekken RA. AXL is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Mol Cancer Res. 2021 Apr 2;molcanres.0860.2020.
Layeghi-Ghalehsoukhteh S, Choudhuri SP, Ocal O, Zolghadri Y, Pashkov V, Niederstrasser H, Posner BA, Kantheti HS, Acevedo-Pouly A, Huang H, MacDonald RJ, Brekken RA, Wilkie TM. Concerted Cell and in vivo Screen for Pancreatic Ductal Adenocarcinoma (PDA) Chemotherapeutics. Sci Rep. 2020 Nov 26;10(1):20662.
Huang H, Brekken RA. Recent Advances in Understanding Cancer-Associated Fibroblasts in Pancreatic Cancer. Am J Physiol Cell Physiol. 2020 Aug 1;319(2):C233-C243.
Huang H, Brekken RA. Beyond Stiffness: Collagen Signaling in Pancreatic Cancer and Pancreas Regeneration. Am J Pathol. 2020 May 22;S0002-9440(20)30245-5.
Huang H, Zhang Y, Gallegos V, Sorrelle N, Zaid MM, Toombs J, Du W, Wright S, Hagopian M, Wang Z, Hosein AN, Sathe AA, Xing C, Koay EJ, Driscoll KE, Brekken RA. Targeting TGFβR2-mutant Tumors Exposes Vulnerabilities to Stromal TGFβ Blockade in Pancreatic Cancer. EMBO Mol Med. 2019 Nov 7;11(11):e10515.
Hosein AN, Huang H, Wang Z, Parmar K, Du W, Huang J, Maitra A, Olson E, Verma U, Brekken RA. Cellular Heterogeneity During Mouse Pancreatic Ductal Adenocarcinoma Progression at Single-Cell Resolution. JCI Insight. 2019 Jul 23;5(16):e129212.
Zhu D*, Huang H*, Pinkas DM, Luo J, Ganguly D, Fox AE, Arner E, Xiang Q, Tu ZC, Bullock AN, Brekken RA, Ding K, Lu X. 2-Amino-2,3-dihydro-1 H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. J Med Chem. 2019 Aug 22;62(16):7431-7444. (*Equal Contribution)
Huang H, Wright S, Zhang J, Brekken RA. Getting a Grip on Adhesion: Cadherin Switching and Collagen Signaling. Biochim Biophys Acta Mol Cell Res. 2019 Nov;1866(11):118472.
Huang H, Brekken RA. The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer. Cancer Res. 2019 Jan 15;79(2):328-330.
Sorrelle N, Ganguly D, Dominguez ATA, Zhang Y, Huang H, Dahal LN, Burton N, Ziemys A, Brekken RA. Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. J Immunol. 2019 Jan 1;202(1):292-299.
Du W*, Huang H*, Sorrelle N, Brekken RA. Sitravatinib Potentiates Immune Checkpoint Blockade in Refractory Cancer Models. JCI Insight. 2018 Nov 2;3(21):e124184. (*Equal Contribution)
Zhang Y, Kirane A, Huang H, Sorrelle NB, Burrows FJ, Dellinger MT, Brekken RA. Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer. Mol Cancer Res. 2019 Feb;17(2):348-355.
Wang Z, Zhang Y, Pinkas DM, Fox AE, Luo J, Huang H, Cui S, Xiang Q, Xu T, Xun Q, Zhu D, Tu Z, Ren X, Brekken RA, Bullock AN, Liang G, Ding K, Lu X. Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- A]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl) phenyl) benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. J Med Chem. 2018 Sep 13;61(17):7977-7990.
Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE. Preclinical Assessment of Galunisertib (LY2157299 Monohydrate), a First-In-Class Transforming Growth factor-β Receptor Type I Inhibitor. Oncotarget. 2017 Dec 31;9(6):6659-6677.
Aguilera KY*, Huang H*, Du W, Hagopian MM, Wang Z, Hinz S, Hwang TH, Wang H, Fleming JB, Castrillon DH, Ren X, Ding K, Brekken RA. Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 Nov;16(11):2473-2485. (*Co-first Authors)
Huang H, Du W, Brekken RA. Extracellular Matrix Induction of Intracellular Reactive Oxygen Species. Antioxid Redox Signal. 2017 Oct 20;27(12):774-784.
Huang H, Svoboda RA, Lazenby AJ, Saowapa J, Chaika N, Ding K, Wheelock MJ, Johnson KR. Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1. J Biol Chem. 2016 Oct 28;291(44):23208-23223.
Liu X, Huang H, Remmers N, Hollingsworth MA. Loss of E-cadherin and Epithelial to Mesenchymal Transition Is Not Required for Cell Motility in Tissues or for Metastasis. Tissue Barriers. 2014 Aug 8;2(4):e969112.
Li Z*, Deng D*, Huang H*, Tian L, Chen Z, Zou Y, Jin G, Wang J, Zhang Q, Wu L, Shen H. Overexpression of Six1 Leads to Retardation of Myogenic Differentiation in C2C12 Myoblasts. Mol Biol Rep. 2013 Jan;40(1):217-23. (*Equal Contribution)